Cargando…

Redefining Remission Induction Chemotherapy Ineligibility by Early Mortality in De Novo Acute Myeloid Leukemia

The therapeutic strategies for acute myeloid leukemia (AML) patients ineligible for remission induction chemotherapy have been improving in the past decade. Therefore, it is important to define ineligibility for remission induction chemotherapy. We retrospectively assessed 153 consecutive adult de n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, You-Cheng, Shih, Yu-Hsuan, Chen, Tsung-Chih, Gau, Jyh-Pyng, Su, Yu-Chen, Chen, Mei-Hui, Hsu, Chiann-Yi, Liao, Cai-Sian, Teng, Chieh-Lin Jerry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708870/ https://www.ncbi.nlm.nih.gov/pubmed/34945065 http://dx.doi.org/10.3390/jcm10245768

Ejemplares similares

Clinical Features and Immunophenotypes of Double-Hit Diffuse Large B-Cell Lymphoma
por: Wu, Cheng-Han, et al.
Publicado: (2022)

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution
por: Lin, Cheng-Hsien, et al.
Publicado: (2022)

Clinical Features and Outcomes of Primary Breast Diffuse Large B-Cell Lymphoma: A Matched-Pair Study
por: Teng, Ling-Chiao, et al.
Publicado: (2023)

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
por: Hung, Yu-Chin, et al.
Publicado: (2021)

Chemoresponse of de novo Acute Myeloid Leukemia to “7+3” Induction can Be Predicted by c-Myc-facilitated Cytogenetics
por: Hsiao, Tzu-Hung, et al.
Publicado: (2021)

A Decade of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: Does the Outcome Improve?
por: Lin, Cheng-Hsien, et al.
Publicado: (2021)

Remission and long-term remission of pediatric-onset systemic lupus erythematosus
por: Chen, Yi-Chieh, et al.
Publicado: (2023)

Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults
por: Tsui, Sze P., et al.
Publicado: (2020)

What’s in a Name? Redefining Type 2 Diabetes Remission
por: Kalra, Sanjay, et al.
Publicado: (2021)

Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study
por: Liao, Po-Wei, et al.
Publicado: (2022)

Redefining Myeloid Cell Subsets in Murine Spleen
por: Hey, Ying-Ying, et al.
Publicado: (2016)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy
por: Minoia, Carla, et al.
Publicado: (2019)

Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies
por: Pettit, Kristen, et al.
Publicado: (2015)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease
por: Ofran, Yishai
Publicado: (2023)

Oral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for Transplantation
por: Choi, Yong Won, et al.
Publicado: (2015)

Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
por: Richard-Carpentier, Guillaume, et al.
Publicado: (2019)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy
por: Shao, I-Hung, et al.
Publicado: (2014)

Association of leukocyte nadir with complete remission in Indonesian acute myeloid leukemia patients undergoing 7+3 remission induction chemotherapy
por: Hadisantoso, Dwi Wahyunianto, et al.
Publicado: (2022)

Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Correction to: Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
Publicado: (2023)

Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
por: Taenaka, Ryutaro, et al.
Publicado: (2022)

Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?
por: Chen, Tsung-Chih, et al.
Publicado: (2020)

Acute Myeloid Leukemia Transformation from Myelofibrosis Upon Remission of an Orbital Myeloid Sarcoma – A Case Report
por: Chen, Nancy, et al.
Publicado: (2021)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
por: Yoo, Kwai Han, et al.
Publicado: (2021)

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study
por: Shih, Yu-Hsuan, et al.
Publicado: (2023)

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study
por: Johnson, Natacha, et al.
Publicado: (2023)

Immunotherapy using BCG during remission induction and as the sole form of maintenance in acute myeloid leukaemia.
por: Summerfield, G. P., et al.
Publicado: (1979)

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups
por: Zehra, Samreen, et al.
Publicado: (2016)

Economic analysis of oral posaconazole prophylaxis in acute myeloid leukemia during remission induction in Turkey
por: Umit, Elif Gulsum, et al.
Publicado: (2020)

BCL2 Expression at Post-Induction and Complete Remission Impact Outcome in Acute Myeloid Leukemia
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2020)

Removal of ineligible outcome cases reduces confounding
por: Walker, Alexander M, et al.
Publicado: (2018)

The Association of Social Support and Symptomatic Remission among Community-Dwelling Schizophrenia Patients: A Cross-Sectional Study
por: Fan, Chi-Hsuan, et al.
Publicado: (2021)

The uniqueness of morphological features of pure erythroid leukemia in myeloid neoplasm with erythroid predominance: A reassessment using criteria revised in the 2016 World Health Organization classification
por: Ko, Po-Shen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8fnavklms2acbl1emlmq9qrkuh